Company: SRPT
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0000950170-25-103971
Chunk: 2

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
47,400

     Other non-current liabilities

     1,204

     1,750

     Total liabilities

     2,322,429

     2,435,431

     Commitments and contingencies (Note 17)

     Stockholders’ equity:

     Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and   outstanding

     —

     —

     Common stock, $0.0001 par value, 198,000,000 shares authorized; 98,356,950 and    97,706,074 issued and outstanding, respectively, at June 30, 2025 and 96,900,496    issued and outstanding at December 31, 2024

     10

     10

     Treasury stock, at cost, 650,876 and 0 shares at June 30, 2025 and    December 31, 2024, respectively

     (25,263
     )

     —

     Additional paid-in capital

     5,844,279

     5,738,924

     Accumulated other comprehensive loss, net of tax

     (51
     )

     (218
     )

     Accumulated deficit

     (4,461,590
     )

     (4,210,974
     )

     Total stockholders’ equity

     1,357,385

     1,527,742

     Total liabilities and stockholders’ equity
      
     $
     3,679,814

     $
     3,963,173

See accompanying notes to unaudited condensed consolidated financial statements.